CH250372A - Process for the preparation of a new oxyhydrophenanthrene derivative. - Google Patents

Process for the preparation of a new oxyhydrophenanthrene derivative.

Info

Publication number
CH250372A
CH250372A CH250372DA CH250372A CH 250372 A CH250372 A CH 250372A CH 250372D A CH250372D A CH 250372DA CH 250372 A CH250372 A CH 250372A
Authority
CH
Switzerland
Prior art keywords
methyl
ethyl
methoxy
tetrahydro
carboxylic acid
Prior art date
Application number
Other languages
German (de)
Inventor
Aktiengesellschaft Ciba
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of CH250372A publication Critical patent/CH250372A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30Unsaturated compounds
    • C07C62/34Unsaturated compounds containing ether groups, groups, groups, or groups

Description

  

  Verfahren zur Herstellung eines neuen     Oxyhydrophenanthren-Derivates.       Es wurde gefunden, dass man zu einem  neuen     Oxyhydrophenanthren-Derivat    gelan  gen kann, wenn man ein     1-Äthyl-2-methyl-          7        --methoxy-1,2,3,4-tetrahydro@-phenanthren,     das     in        2-Stellung    einen durch Hydrolyse in  die freie     Carboxylgruppe        überführbaren        Sub-          stituenten,    z.

   B. eine     veresterte        Carboxyl-          gruppe,    enthält, zwecks     Bildung    einer freien       Carboxylgruppe    mit     hydrolysierenden    Mit  teln behandelt.  



  Das noch nicht bekannte Endprodukt des  Verfahrens, die     1-Äthyl-2-methyl-7-methoxy-          1,2,3,4    -     tetrahydro    -     phenanthren    - 2 -     carbon-          säure    vom F. 228-230 ,     zeigt    sowohl bei       parenteraler    als auch bei oraler     Applikation     eine     ausserordentlich    hohe     oestrogene    Wir  kung.

   Es soll     therapeutische    Verwendung       finden    oder als Zwischenprodukt zur Herstel  lung     therapeutisch    verwendbarer Verbindun  gen dienen.  



  Für die Überführung des     Substituenten     in     2-Stellung    in die freie     Carboxylgruppe     verwendet man     beispielsweise    anorganische  Basen, wie Alkali- oder     Erdalkalihydroxyde.     



  Die     Ausgangsstoffe    werden z. B. erhalten  aus     1-geto-2-methyl-7-methoxy-1,2,3,4-tetra-          hydro-phenanthrenen,    die in     2-Stellung    einen  durch Hydrolyse in die freie     Carboxylgruppe          überführbaren        Substituenten        aufweisen,        durch          Grignardierung    mit einem     Äthylmagnesium-          halogenid,

          Wasserabspaltung        aus    dem so er  haltenen     1-Äthyl-l-oxy-2-methyl-7-methoxy-          1,2,3,4-tetrahydro-phenanthren-Derivat    und    anschliessende     Hydrierung    der gebildeten  Doppelbindung.  



  <I>Beispiel:</I>  <B>3,3</B>     Gewichtsteile    1- Äthyl - 2 -     methyl-7-          methoxy    -1,2,3,4     -tetrahydro        -phenanthren    - 2  carbonsäuremethylester vom F. 76-78  und  der     Formel     
EMI0001.0060     
    werden in einer     Mischung    von 16,5 Gewichts  teilen     galiumhydroxyd,    5     Volumteilen    Wasser  und 10     Volumteilen    Alkohol auf 160  er  hitzt.

   Nach dem Verdampfen des Alkohols       kristallisiert    noch     in.    der Wärme das Kalium  salz der     Carbonsäure        aus.    Dieses     nimmt    man  in 100     Volumteilen    Wasser auf, worauf sich  nach kurzer Zeit das schwer lösliche Kalium  salz in glänzenden Plättchen ausscheidet.

    Durch Zersetzen mit     verdünnter    Salzsäure  wird daraus die     oestrogen        wirksame        1-Äthyl-          2    -     methyl    - 7 -     methoxy    -1,2,3,4 -     tetrahydro-          phenanthren-2-carbonsäure    der Formel  
EMI0001.0080     
      erhalten, die nach     ümlösen        aus        Aceton    bei  228-230      schmilzt.     



  Den     Ausgangsstoff    erhält man z. B. wie  folgt: 12     Gewichtsteile        1-geto-2-methyl-7-          methoxy    -1,2,3,4 -     tetrahydro-        phenanthren-        2-          carbonsäuremethylester    lässt man mit einer       Grignard-Lösung,        hergestellt    aus 1,25     Ge-          wichtsteilen    Magnesium und 5     Volumteilen          Äthylbromid,    reagieren,

   kocht 8     Gewichts-          teile    des so gewonnenen     1-Äthyl-l-oxy-2-          methyl    -1,2,3,4 -     tetrahydro    -     phenanthren    - 2     -          carbonsäuremethylesters    vom F.

   153      zwecks          Wasserabspaltung    in     einer    Lösung von 0,3       Gewichtsteilen    Jod     in    40     Volumteilen    Chloro  form     und        hydriert    1     Gewichtsteil    der       Äthyliden-Verbindung    in 30     Volumteilen     Alkohol in Gegenwart von 0,1 Gewichtsteil  eines     Plationkatalysators    zum     1-Äthyl    - 2     -          methyl-        7-methoxy-1,2,3,

  4-tetrahydro-phen-          anthren-2-carbonsäuremethylester    vom F. 76  bis 78 .



  Process for the preparation of a new oxyhydrophenanthrene derivative. It has been found that a new oxyhydrophenanthrene derivative can be obtained if a 1-ethyl-2-methyl-7-methoxy-1,2,3,4-tetrahydro @ -phenanthrene which is in the 2-position a substituent which can be converted into the free carboxyl group by hydrolysis, e.g.

   B. contains an esterified carboxyl group, treated with hydrolyzing agents to form a free carboxyl group.



  The as yet unknown end product of the process, the 1-ethyl-2-methyl-7-methoxy-1,2,3,4-tetrahydro-phenanthrene-2-carboxylic acid from F. 228-230, shows both parenteral and an extraordinarily high estrogenic effect even with oral application.

   It is intended to be used therapeutically or as an intermediate for the manufacture of therapeutically usable compounds.



  For example, inorganic bases, such as alkali or alkaline earth metal hydroxides, are used to convert the substituent in the 2-position into the free carboxyl group.



  The starting materials are z. B. obtained from 1-geto-2-methyl-7-methoxy-1,2,3,4-tetra- hydro-phenanthrenes which have a substituent which can be converted into the free carboxyl group by hydrolysis, by Grignardation with a Ethyl magnesium halide,

          Elimination of water from the 1-ethyl-l-oxy-2-methyl-7-methoxy-1,2,3,4-tetrahydro-phenanthrene derivative obtained in this way and subsequent hydrogenation of the double bond formed.



  <I> Example: </I> <B> 3.3 </B> parts by weight of 1- ethyl - 2 - methyl-7-methoxy -1,2,3,4-tetrahydro-phenanthrene - 2 carboxylic acid methyl ester of F. 76 -78 and the formula
EMI0001.0060
    are in a mixture of 16.5 parts by weight of galium hydroxide, 5 parts by volume of water and 10 parts by volume of alcohol to 160 he heats.

   After the alcohol has evaporated, the potassium salt of the carboxylic acid crystallizes in the heat. This is taken up in 100 parts by volume of water, whereupon the poorly soluble potassium salt precipitates in shiny platelets after a short time.

    By decomposing it with dilute hydrochloric acid, it becomes the estrogenically active 1-ethyl-2-methyl-7-methoxy-1,2,3,4-tetrahydro- phenanthrene-2-carboxylic acid of the formula
EMI0001.0080
      obtained, which melts at 228-230 after dissolving from acetone.



  The starting material is obtained z. B. as follows: 12 parts by weight of 1-geto-2-methyl-7-methoxy -1,2,3,4-tetrahydro- phenanthrene-2-carboxylic acid methyl ester are left with a Grignard solution, prepared from 1.25 parts by weight Magnesium and 5 parts by volume of ethyl bromide, react,

   boils 8 parts by weight of the 1-ethyl-l-oxy-2-methyl -1,2,3,4-tetrahydro-phenanthrene-2-carboxylic acid methyl ester of F.

   153 for the purpose of dehydration in a solution of 0.3 parts by weight of iodine in 40 parts by volume of chloro form and hydrogenated 1 part by weight of the ethylidene compound in 30 parts by volume of alcohol in the presence of 0.1 part by weight of a Plation catalyst to 1-ethyl - 2 - methyl-7-methoxy -1,2,3,

  4-tetrahydro-phen-anthrene-2-carboxylic acid methyl ester with a melting point of 76 to 78.

 

Claims (1)

PATENTANSPRUCH: Verfahren zur Herstellung eines neuen Oxyhydrophenanthren-Derivates, dadurch ge- kennzeichnet, dass man ein 1-Äthyl-2-methyl- 7 4 methoxy-1,2,3,4 - tetrahydro- phenanthren, PATENT CLAIM: Process for the production of a new oxyhydrophenanthrene derivative, characterized in that a 1-ethyl-2-methyl-7 4 methoxy-1,2,3,4-tetrahydrophenanthrene, das in 2-Stellung einen durch Hydrolyse in die freie Carboxylgruppe überführbaren Sub- stituenten enthält, zwecks Bildung einer freien Carboxy lgruppe mit hydrolysierenden Mitteln behandelt. which contains a substituent which can be converted into the free carboxyl group by hydrolysis in the 2-position, treated with hydrolyzing agents in order to form a free carboxyl group. Das noch nicht bekannte Endprodukt des Verfahrens, die 1-Äthyl-2-methyl-7-methoxy- 1,2,3,4 - tetrahydro - phenanthren - 2 - carbon- säur.e vom F. 228-230 , zeigt sowohl bei parenteraler als auch bei oraler Applikation eine ausserordentlich hohe oestrogene Wir kung. Es soll therapeutische Verwendung finden oder als Zwischenprodukt zur Herstel lung therapeutisch verwendbarer Verbindun gen dienen. UNTERANSPRüCHE 1. The as yet unknown end product of the process, the 1-ethyl-2-methyl-7-methoxy-1,2,3,4-tetrahydro-phenanthrene-2-carboxylic acid from F. 228-230, shows both at Parenteral as well as oral administration an extraordinarily high estrogenic effect. It is intended to be used therapeutically or as an intermediate for the manufacture of therapeutically usable compounds. SUBCLAIMS 1. Verfahren nach Patentanspruch, da durch gekennzeichnet, dass man als Aus gangsstoff einen 1-Äthyl-2-methyl-7-meth oxy-1,2,3,4-tetrahydro-phenanthren-2-carbon- säureester verwendet. 2. Verfahren nach Patentansprueh und Unteranspruch 1, dadurch gekennzeichnet, dass man als Ausgangsstoff den 1-Äthyl-2- methyl- 7 -methoxy-1,2,3,4-tetrahydro-phen- anthren-2-carbonsäuremethylester verwendet. 3. Process according to patent claim, characterized in that a 1-ethyl-2-methyl-7-methoxy-1,2,3,4-tetrahydro-phenanthrene-2-carboxylic acid ester is used as the starting material. 2. The method according to patent claim and dependent claim 1, characterized in that 1-ethyl-2-methyl-7-methoxy-1,2,3,4-tetrahydro-phen-anthrene-2-carboxylic acid methyl ester is used as the starting material. 3. Verfahren nach Patentanspruch und den Unteransprüchen 1 und 2, dadurch ge kennzeichnet, dass man als hydrolysierende Mittel anorganische Basen verwendet. Process according to patent claim and dependent claims 1 and 2, characterized in that inorganic bases are used as the hydrolyzing agent.
CH250372D 1944-01-10 1944-01-10 Process for the preparation of a new oxyhydrophenanthrene derivative. CH250372A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH250372T 1944-01-10

Publications (1)

Publication Number Publication Date
CH250372A true CH250372A (en) 1947-08-31

Family

ID=4468163

Family Applications (1)

Application Number Title Priority Date Filing Date
CH250372D CH250372A (en) 1944-01-10 1944-01-10 Process for the preparation of a new oxyhydrophenanthrene derivative.

Country Status (1)

Country Link
CH (1) CH250372A (en)

Similar Documents

Publication Publication Date Title
CH250372A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258172A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258173A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258175A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH250806A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258177A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
DE1593315B1 (en) 9-isopropylidene-9,10-dihydroanthracene-10-carboxylic acid-ß-diaethylamino-ethyl ester, their salts and process for their preparation
CH258179A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
DE934103C (en) Process for the production of cyclooctylated alkyl acetic acids with a strong cholagogue effect
AT227256B (en) Process for the production of new aminoindanes and their salts
CH258188A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258178A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH227069A (en) Process for the preparation of a cyclopentano-dimethyl-polyhydrophenanthrene-carboxylic acid.
CH258176A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
DE887815C (en) Process for the preparation of disubstituted carboxylic acid diamides
CH258189A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
AT158268B (en) Process for the preparation of androstenedione- (3.17) or androstenol- (17) -onen- (3).
AT159962B (en) Process for the preparation of esters of the adrenal cortical hormones or largely purified adrenal cortical hormones.
DE849242C (en) Process for the preparation of diadipic acid
DE1253266B (en) Process for the production of dioxocyclobutene diol
CH258187A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH242609A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH306287A (en) Process for the preparation of a piperidine derivative.
CH258174A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258180A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.